B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 11.8 NOK -5.9% Market Closed
Market Cap: 479.2m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

Bergenbio ASA
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bergenbio ASA
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
B
Bergenbio ASA
OSE:BGBIO
Other Current Liabilities
kr33.6m
CAGR 3-Years
-7%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Other Current Liabilities
kr10.3m
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
7%
L
Lytix Biopharma AS
OSE:LYTIX
Other Current Liabilities
kr8.5m
CAGR 3-Years
-3%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
N
Nykode Therapeutics ASA
OSE:NYKD
Other Current Liabilities
$10.3m
CAGR 3-Years
38%
CAGR 5-Years
68%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Other Current Liabilities
kr1.8m
CAGR 3-Years
-72%
CAGR 5-Years
-52%
CAGR 10-Years
-8%
No Stocks Found

Bergenbio ASA
Glance View

Market Cap
461.2m NOK
Industry
Biotechnology

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

BGBIO Intrinsic Value
0.2 NOK
Overvaluation 98%
Intrinsic Value
Price
B

See Also

What is Bergenbio ASA's Other Current Liabilities?
Other Current Liabilities
33.6m NOK

Based on the financial report for Sep 30, 2024, Bergenbio ASA's Other Current Liabilities amounts to 33.6m NOK.

What is Bergenbio ASA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
11%

Over the last year, the Other Current Liabilities growth was 189%. The average annual Other Current Liabilities growth rates for Bergenbio ASA have been -7% over the past three years , 11% over the past five years .

Back to Top